Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists

31 August 2019 (12:12 - 12:30)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Naveed Sattar

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail

State of the Art - SGLT2 inhibitors in cardiovascular disease

Professor M. Sabatine (Boston, US)

Presentation thumbnail

Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

Doctor T. Zelniker (Vienna, AT)

Abstract Slides Video

Presentation thumbnail

Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

Doctor J. Udell (Toronto, CA)

Abstract Slides Video

Presentation thumbnail

SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes

Doctor C. Noergaard (Aalborg, DK)

Abstract Slides Video

Access the full session

Session thumbnail

New frontiers: SGLT2 inhibitors in cardiorenal disease

The Event

ESC Congress 2019

31 August 2019 12:12 CET

You may be interested in

Congress Session

Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

Congress Session

2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

Congress Presentation

Antithrombotic therapy in diabetes

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources